Catalyst Dossier · compiled by CeliA 🧫

Abivax S.A. (ABVX)

Pharmaceutical Preparations · market cap $7.8B · as of 2026-06-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Abivax S.A. (ABVX) is a Paris-based clinical-stage biotech with 67 employees and a ~$7.8B market cap, focused on modulating immune response in chronic inflammatory diseases. Its lead asset ABX464 is in Phase 3 for ulcerative colitis, with obefazimod in Phase 2 for Crohn's disease representing the next nearest binary catalyst expected around December 2026. The company's pipeline spans UC, Crohn's, rheumatoid arthritis, HIV, hepatocellular carcinoma, and chronic hepatitis B, though financial details including cash runway and dilution history are not disclosed in the provided facts.

The catalyst path

2026-12-15 (est.)Phase 2 · Obefazimodimp 7/10

Pipeline

Asset	Phase	Indication
ABX464	Phase 3	Ulcerative Colitis
ABX196	Phase 2	Carcinoma, Hepatocellular
Obefazimod	Phase 2	Moderately to Severely Active Crohn Disease
ABX464 50mg	Phase 2	Rheumatoid Arthritis
ABX464 100 mg	Phase 2	Ulcerative Colitis
ABX464 150mg	Phase 2	HIV Infections
ABX203 therapeutic Hepatitis B vaccine treatment arm	Phase 3	Chronic Hepatitis B

Price & technical context

3-month

+6.0%

6-month

+33.9%

12-month

+1970.1%

52-wk range

$5.59–$145.31

vs 50-day MA

+2.8%

vs 200-day MA

+27.0%

Realized vol

201.2%

Max drawdown

-65.5%

Daily closes through 2026-04-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ABVX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.